Hologic adds SARS-CoV-2 test to global testing project

By LabPulse.com staff writers

January 5, 2022 -- Hologic has added its Aptima SARS-CoV-2 assay to the company's Global Access Initiative (GAI), a program that is intended to expand access to critical diagnostic testing in resource-limited countries.

Hologic launched GAI at the 2018 International AIDS Conference as an initiative to offer an all-inclusive pricing structure with no upfront cost or capital expenditure. In addition to the SARS-CoV-2 assay, the company offers other tests in the initiative, including tests for HIV-1, hepatitis B and C, and HPV.

The Aptima assay is available through the World Health Organization Diagnostics Consortium, which helps middle- and low-income countries secure critical quantities of diagnostic tests.

Hologic receives CE Mark for Genius cervical cancer software
Hologic has received the CE Mark for its Genius Cervical AI software for cervical cancer screening. The software uses artificial intelligence to analyze...
Hologic posts slight Q4 revenue decrease
Hologic posted a slight decrease in revenue for the company's fourth quarter, which it attributed to lower demand for its SARS-CoV-2 assays compared with...
Hologic launches multiplex COVID/flu assay
Hologic's Aptima SARS-CoV-2/flu assay is now commercially available in North America and Europe for the simultaneous detection and differentiation of...
Hologic launches on-demand molecular testing in Europe
Hologic has launched its Novodiag on-demand molecular test for infectious diseases and antibiotic resistance in Europe.
Hologic posts strong Q3 revenues
Hologic posted strong revenues for its fiscal third quarter. The company attributed the solid financial results in part to recovery from the COVID-19...

Copyright © 2022 LabPulse.com

Last Updated ls 1/6/2022 12:59:31 PM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current